Total-Body 18 F-FAPI PET/CT for Assessment of Metabolic Dysfunction–Associated Steatotic Liver Disease: A Pilot Study

Liver biopsy remains the gold standard for fibrosis assessment; however, its invasiveness limits its suitability for routine clinical use. The rising prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) as a leading cause of chronic liver disease and hepatocellular carcinoma underscores the need for reliable noninvasive assessment. Current noninvasive imaging methods provide surrogate measures of fibrosis but do not directly assess fibrogenic activity. In contrast, fibroblast activation protein inhibitor (FAPI) PET enables molecular imaging of activated fibroblasts, a key driver of fibrosis. This study evaluates dynamic 18F-FAPI-74 PET imaging to assess hepatic fibrogenic activity in MASLD. Methods: In this prospective pilot study, 10 subjects (3 healthy volunteers, 4 patients with mild–moderate fibrosis, and 3 patients with advanced fibrosis) underwent 60-min dynamic 18F-FAPI-74 PET/CT. SUV and blood-normalized SUV ratio (SUVR) were quantified across time frames, and the net influx rate was derived from dynamic data. MR elastography–derived liver stiffness values were obtained for comparison. Correlations with histologic fibrosis scoring of biopsy tissue were assessed using Spearman analysis. Results: At 5 min postinjection, SUVR correlated strongly with histologic fibrosis score (ρ = 0.95; 95% CI, 0.75–1.00; P = 1.89 × 10−5), followed by SUV (ρ = 0.78; 95% CI, 0.23–0.98; P = 0.0077) and net influx rate from kinetic modeling (ρ = 0.84; 95% CI, 0.41–0.98; P = 0.0022). SUVR at the 4- to 5-min interval allowed clearer differentiation among healthy volunteers, patients with mild fibrosis, and patients with advanced fibrosis. Conclusion: Dynamic 18F-FAPI-74 PET enables quantitative visualization of hepatic fibroblast activation in MASLD. SUVR at the 4- to 5-min interval correlates more strongly with fibrosis severity, supporting 18F-FAPI-74 PET as a promising molecular biomarker for assessing and potentially monitoring metabolic fibrosis.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2026-11-12
DOI
https://doi.org/10.2967/jnumed.126.272994
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Total-Body 18 F-FAPI PET/CT for Assessment of Metabolic Dysfunction–Associated Steatotic Liver Disease: A Pilot Study

Kevin J. Chung, Lorenzo Nardo, Victoria Lyo, Ramsey Derek Badawi et al.
Journal of Nuclear Medicine
Liver Disease Diagnosis and Treatment
article

Total-Body 18 F-FAPI PET/CT for Assessment of Metabolic Dysfunction–Associated Steatotic Liver Disease: A Pilot Study

Kevin J. Chung, Lorenzo Nardo, Victoria Lyo, Ramsey Derek Badawi, Ilke Tunali, Adam T. Hoye, Yasser G. Abdelhafez, Anne McGeehan, Michael T. Corwin, Valentina Medici, Pascale N. Lacor, Emily C. Collins, Benjamin A. Spencer, Molly Johnson, Shivani Malige, Matthew Flitter, Guobao Wang, Karen Matsukuma, Xiaoyu Duan
article en

Abstract

Liver biopsy remains the gold standard for fibrosis assessment; however, its invasiveness limits its suitability for routine clinical use. The rising prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) as a leading cause of chronic liver disease and hepatocellular carcinoma underscores the need for reliable noninvasive assessment. Current noninvasive imaging methods provide surrogate measures of fibrosis but do not directly assess fibrogenic activity. In contrast, fibroblast activation protein inhibitor (FAPI) PET enables molecular imaging of activated fibroblasts, a key driver of fibrosis. This study evaluates dynamic 18F-FAPI-74 PET imaging to assess hepatic fibrogenic activity in MASLD. Methods: In this prospective pilot study, 10 subjects (3 healthy volunteers, 4 patients with mild–moderate fibrosis, and 3 patients with advanced fibrosis) underwent 60-min dynamic 18F-FAPI-74 PET/CT. SUV and blood-normalized SUV ratio (SUVR) were quantified across time frames, and the net influx rate was derived from dynamic data. MR elastography–derived liver stiffness values were obtained for comparison. Correlations with histologic fibrosis scoring of biopsy tissue were assessed using Spearman analysis. Results: At 5 min postinjection, SUVR correlated strongly with histologic fibrosis score (ρ = 0.95; 95% CI, 0.75–1.00; P = 1.89 × 10−5), followed by SUV (ρ = 0.78; 95% CI, 0.23–0.98; P = 0.0077) and net influx rate from kinetic modeling (ρ = 0.84; 95% CI, 0.41–0.98; P = 0.0022). SUVR at the 4- to 5-min interval allowed clearer differentiation among healthy volunteers, patients with mild fibrosis, and patients with advanced fibrosis. Conclusion: Dynamic 18F-FAPI-74 PET enables quantitative visualization of hepatic fibroblast activation in MASLD. SUVR at the 4- to 5-min interval correlates more strongly with fibrosis severity, supporting 18F-FAPI-74 PET as a promising molecular biomarker for assessing and potentially monitoring metabolic fibrosis.

Journal of Nuclear Medicine
Eli Lilly (United States) (US), University of California Davis Medical Center (US), UC Davis Health (US), University of California, Davis (US), Assiut University (EG)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon